W tym dziale chcemy stworzyć wyczerpującą bibliografię publikacji na temat psychodelików. Zawiera ona wszystkie źródła, jakie pojawiły się w naszych artykułach, a także wiele innych, dodanych przez naszych czytelników.

Możesz pobrać poszczególne pozycje w formacie RIS, aby zaimportować je do swojego programu referencyjnego, klikając link (CITE). My używamy i polecamy Zotero. Jeśli uważasz, że brakuje tutaj jakiegoś tytułu, wypełnij ten formularz. Prosimy o podanie referencji w formacie APA oraz dołączenie identyfikatora DOI.

Wyszukaj artykuł:



Abdallah, C. G., Averill, L. A., Collins, K. A., Geha, P., Schwartz, J., Averill, C., DeWilde, K. E., Wong, E., Anticevic, A., Tang, C. Y., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2017). Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology, 42(6), 1210–1219. https://doi.org/10.1038/npp.2016.186 Cite
Adams, M. (2020, January 28). Could psychedelics help us resolve the climate crisis? The Conversation. https://theconversation.com/could-psychedelics-help-us-resolve-the-climate-crisis-129639 Cite
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2020). Psychedelics and virtual reality: parallels and applications. Therapeutic Advances in Psychopharmacology, 10, 2045125320948356. https://doi.org/10.1177/2045125320948356 Cite
Aday, J. S., Wood, J. R., Bloesch, E. K., & Davoli, C. C. (2021). Psychedelic drugs and perception: a narrative review of the first era of research. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro-2020-0094 Cite
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2020.03.017 Cite
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019). Can psychedelic drugs attenuate age-related changes in cognition and affect? Journal of Cognitive Enhancement. https://doi.org/10.1007/s41465-019-00151-6 Cite
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2020). 2019: A year of expansion in psychedelic research, industry, and deregulation. Drug Science, Policy and Law, 6, 2050324520974484. https://doi.org/10.1177/2050324520974484 Cite
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019). Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century. Journal of Psychoactive Drugs, 51(3), 210–217. https://doi.org/10.1080/02791072.2019.1581961 Cite
Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155–166. https://doi.org/10.1177/0269881119897615 Cite
Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021). Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology & Translational Science, 4(2), 543–552. https://doi.org/10.1021/acsptsci.1c00018 Cite
Agrawal, M. (2021). The tip of the iceberg: Addressing mental health in cancer. Psychology Today. https://www.psychologytoday.com/us/blog/pathways-progress/202103/the-tip-the-iceberg-addressing-mental-health-in-cancer?eml Cite
Aixalà, M., dos Santos, R. G., Hallak, J. E. C., & Bouso, J. C. (2018). Psychedelics and personality. ACS Chemical Neuroscience, 9(10), 2304–2306. https://doi.org/10.1021/acschemneuro.8b00237 Cite
Aixalá, M., Ona, G., Parés, Ò., & Bouso, J. C. (2019). Patterns of use, desired effects, and mental health status of a sample of natural psychoactive drug users. Drugs: Education, Prevention and Policy, 1–8. https://doi.org/10.1080/09687637.2019.1611739 Cite
Altman, B. R., Mian, M. N., & Earleywine, M. (2020). The Novelty of Ayahuasca Scale and the prediction of intentions to use. Journal of Psychedelic Studies. https://doi.org/10.1556/2054.2020.00117 Cite
Alzweiri, M., Alsegiani, A., Karaj, E., Almarghalani, D., Tabaza, Y., Shah, Z., & Tillekeratne, V. (2021). The structural simplification of lysergic acid as a natural lead for synthesizing novel anti-Alzheimer agents. Bioorganic & Medicinal Chemistry Letters, 128205. https://doi.org/10.1016/j.bmcl.2021.128205 Cite
Amigó, S., & Ferrández, C. (2015). Experiencing Effects of Cocaine and Speed with Self-Regulation Therapy. The Spanish Journal of Psychology, 18, E49. Cambridge Core. https://doi.org/10.1017/sjp.2015.50 Cite
Amigó, S., Caselles, A., & Micó, J. C. (2013). Self-Regulation Therapy to Reproduce Drug Effects: A Suggestion Technique to Change Personality and the DRD3 Gene Expression. International Journal of Clinical and Experimental Hypnosis, 61(3), 282–304. https://doi.org/10.1080/00207144.2013.784094 Cite
Amoroso, T. (2019). The spurious relationship between ecstasy use and neurocognitive deficits: A Bradford Hill review. International Journal of Drug Policy, 64, 47–53. https://doi.org/10.1016/j.drugpo.2018.11.002 Cite
Amoroso, T. (2018). Are the neurocognitive deficits associated with 3,4-methylenedioxymethamphetamine caused by statistical deficits in ecstasy research? A systematic review. Drug Science, Policy and Law, 4, 2050324518789214. https://doi.org/10.1177/2050324518789214 Cite
Amoroso, T., & Workman, M. (2016). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology, 30(7), 595–600. https://doi.org/10.1177/0269881116642542 Cite
Andersen, K. A. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica, 143(2), 101–118. https://doi.org/10.1111/acps.13249 Cite
Anderson, K. (2017). Navigating intimacy with ecstasy: The emotional, spatial and boundaried dynamics of couples’ MDMA experiences [London South Bank University]. https://www.researchgate.net/publication/328319587_Navigating_intimacy_with_ecstasy_The_emotional_spatial_and_boundaried_dynamics_of_couples%27_MDMA_experiences?channel=doi&linkId=5bc65103458515f7d9bf8f15&showFulltext=true Cite
Anderson, B., Danforth, A., Daroff, R., Stauffer, C., Dilley, J., Mitchell, J., & Woolley, J. (2019). T137. Psilocybin-Assisted Group Therapy for Demoralization in Long-Term AIDS Survivors. Biological Psychiatry, 85(10), S182. https://doi.org/10.1016/j.biopsych.2019.03.460 Cite
Anderson, T., Petranker, R., Christopher, A., Rosenbaum, D., Weissman, C., Dinh-Williams, L.-A., Hui, K., & Hapke, E. (2019). Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduction Journal, 16(1), 43–43. PubMed. https://doi.org/10.1186/s12954-019-0308-4 Cite
Anderson, B. T., Danforth, A., Daroff, P. R., Stauffer, C., Ekman, E., Agin-Liebes, G., Trope, A., Boden, M. T., Dilley, P. J., Mitchell, J., & Woolley, J. (2020). Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine, 27. https://doi.org/10.1016/j.eclinm.2020.100538 Cite
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. %J P. (2019). Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology. https://doi.org/10.1007/s00213-018-5106-2 Cite
Anderson, K., Reavey, P., & Boden, Z. (2019). ‘Never drop without your significant other, cause that way lies ruin’: The boundary work of couples who use MDMA together. International Journal of Drug Policy, 71, 10–18. https://doi.org/10.1016/j.drugpo.2019.05.004 Cite
Andersson, M., & Kjellgren, A. (2019). Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube. Harm Reduction Journal, 16(1), 63. https://doi.org/10.1186/s12954-019-0333-3 Cite
Anthony, J., Winstock, A., Ferris, J., & Nutt, D. (2020). Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017. Drug Science, Policy and Law, 6, 2050324520942345. https://doi.org/10.1177/2050324520942345 Cite
Apud Peláez, I. E. (2020). Personality Traits in Former Spanish Substance Users Recovered with Ayahuasca. Journal of Psychoactive Drugs, 52(3), 264–272. https://doi.org/10.1080/02791072.2020.1752960 Cite
Argento, E., Tupper, K. W., & Socias, M. E. (2019). The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis. International Journal of Drug Policy, 66, 80–81. https://doi.org/10.1016/j.drugpo.2018.11.006 Cite
Argento, E., Braschel, M., Walsh, Z., Socias, M. E., & Shannon, K. (2018). The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. Journal of Psychopharmacology, 32(12), 1385–1391. https://doi.org/10.1177/0269881118798610 Cite
Asmussen Frank, V., MacLean, S., & Herold Maria, D. (2020). Nitrous oxide use among young people – new trends, policy challenges, and knowledge gaps. Drugs and Alcohol Today, 20(4), 383–392. https://doi.org/10.1108/DAT-09-2020-0062 Cite
Austin, E., Myron, H. S., Summerbell, R. K., & Mackenzie, C. A. (2019). Acute renal injury cause by confirmed Psilocybe cubensis mushroom ingestion. Medical Mycology Case Reports, 23, 55–57. https://doi.org/10.1016/j.mmcr.2018.12.007 Cite
Azhari, N., Hu, H., O’Malley, K. Y., Blocker, M. E., Levin, F. R., & Dakwar, E. (2020). Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study. Am J Drug Alcohol Abuse, 1–6. https://doi.org/10.1080/00952990.2020.1808982 Cite
Baggott, M. J. (2015). Psychedelics and creativitiy: a review of the quantitative literature. Peer J Preprints. https://peerj.com/preprints/1202v1/ Cite
Baggott, M. J., Erowid, E., Erowid, F., Galloway, G. P., & Mendelson, J. (2010). Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend, 111(3), 250–256. https://doi.org/10.1016/j.drugalcdep.2010.05.003 Cite
Baggott, M. J., Garrison, K. J., Coyle, J. R., Galloway, G. P., Barnes, A. J., Huestis, M. A., & Mendelson, J. E. (2016). MDMA Impairs Response to Water Intake in Healthy Volunteers. Adv Pharmacol Sci, 2016, 2175896. https://doi.org/10.1155/2016/2175896 Cite
Baggott, M. J., Kirkpatrick, M. G., Bedi, G., & de Wit, H. (2015). Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol, 29(6), 669–677. https://doi.org/10.1177/0269881115581962 Cite
Baggott, M. J., Garrison, K. J., Coyle, J. R., Galloway, G. P., Barnes, A. J., Huestis, M. A., & Mendelson, J. E. (2019). Effects of the psychedelic amphetamine MDA (3,4-Methylenedioxyamphetamine) in healthy volunteers. J Psychoactive Drugs, 51(2), 108–117. https://doi.org/10.1080/02791072.2019.1593560 Cite
Baggott, M. J., Coyle, J. R., Siegrist, J. D., Garrison, K. J., Galloway, G. P., & Mendelson, J. E. (2016). Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol, 30(4), 378–387. https://doi.org/10.1177/0269881115626348 Cite
Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend, 114(1), 61–67. https://doi.org/10.1016/j.drugalcdep.2010.09.006 Cite
Bahji, A., Zarate, C. A., Jr, & Vazquez, G. H. (2021). Ketamine for bipolar depression: A systematic review. International Journal of Neuropsychopharmacology, 24(7), 535–541. https://doi.org/10.1093/ijnp/pyab023 Cite
Ballew, M., & Omoto, A. (2018). Absorption: how nature experiences promote awe and other positive emotions. Ecopsychology, 10(1), 26–35. https://doi.org/10.1089/eco.2017.0044 Cite
Barnby, J. M., & Mehta, M. A. (2018). Psilocybin and mental health - don’t lose control. Frontiers in Psychiatry, 9, 293–293. PubMed. https://doi.org/10.3389/fpsyt.2018.00293 Cite
Barnett, B. S., & Greer, G. R. (2021). Psychedelic psychiatry and the C-L psychiatrist: A primer. Journal of the Academy of Consultation-Liaison Psychiatry. https://doi.org/10.1016/j.jaclp.2020.12.011 Cite
Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. (2020). Decreased directed functional connectivity in the psychedelic state. NeuroImage, 209, 116462. https://doi.org/10.1016/j.neuroimage.2019.116462 Cite
Barrett, F. S., & Griffiths, R. R. (2018). Classic hallucinogens and mystical experiences: phenomenology and neural correlates. In A. L. Halberstadt, F. X. Vollenweider, & D. E. Nichols (Eds.), Behavioral Neurobiology of Psychedelic Drugs (pp. 393–430). Springer Berlin Heidelberg. https://doi.org/10.1007/7854_2017_474 Cite
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182–1190. https://doi.org/10.1177/0269881115609019 Cite
Barrett, F. S., Robbins, H., Smooke, D., Brown, J. L., & Griffiths, R. R. (2017). Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Frontiers in Psychology, 8(1238). https://doi.org/10.3389/fpsyg.2017.01238 Cite

Zapisz się do newslettera, aby otrzymywać najnowsze informacje.

Obrazek: Image by Gerd Altmann from Pixabay